Telomir Pharmaceuticals Publishes Preclinical Study Showing Telomir‑Zn Benefits

What Happened

• On September 17, 2026, Telomir Pharmaceuticals, Inc. (TELO) announced the publication of a peer‑reviewed preclinical study in International Journal of Molecular Sciences (2026; 27(18), 8265) titled “Targeted Intracellular Metal Modulation Attenuates Oxidative Stress and Preserves Retinal Integrity and Function in a Zebrafish Model of Mitochondrial Dysfunction and Age‑Related Retinal Degeneration.”
• The study reported that 14 days of oral Telomir‑Zn treatment restored visual function and retinal structure in a zebrafish model of age‑related macular degeneration (AMD), including restoration of retinal layer thickness, reduced mitochondrial oxidative stress, a dose‑dependent increase in relative telomeric DNA content, and reversal of altered DNA methylation at selected aging‑associated CpG loci.
• Complementary mechanistic data showed Telomir‑Zn reduced labile intracellular Fe2+, increased intracellular zinc, and inhibited Fe2+‑dependent Jumonji C histone demethylases (KDMs), linking metal modulation to epigenetic effects. The company reiterated its clinical focus on oncology; Telomir‑Zn is advancing under an FDA‑cleared IND for a Phase 1/2 trial in advanced or metastatic triple‑negative breast cancer (TNBC).

Key Details

• Filing date: September 17, 2026 (Form 8‑K Regulation FD disclosure).
• Publication: International Journal of Molecular Sciences, 2026;27(18):8265 (peer‑reviewed).
• Preclinical regimen: 14 days oral Telomir‑Zn in a zebrafish AMD model with measurable restoration of retinal structure and function.
• Clinical status: Telomir‑Zn is under an FDA‑cleared IND for a Phase 1/2 clinical trial in advanced/metastatic TNBC.

Why It Matters

• The announcement adds peer‑reviewed preclinical evidence supporting Telomir‑Zn’s proposed mechanism (intracellular metal homeostasis and epigenetic regulation), which the company says may have relevance beyond its current oncology program.
• For investors, this is a scientific validation milestone (publication in a peer‑reviewed journal) but not clinical proof of efficacy in humans; Telomir‑Zn’s human safety and efficacy remain to be established in the ongoing/planned clinical trial under the IND.
• The company included standard forward‑looking statement cautioning that development, regulatory, and clinical risks may affect outcomes; investors should consider this alongside Telomir’s SEC filings for risk factors and updates.